Literature DB >> 25600095

Kidney cancer: Systemic therapy--differentiating the achievable from the achieved.

Reza Mehrazin1, Matthew D Galsky2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25600095     DOI： 10.1038/nrurol.2014.358

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  7 in total

1.  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

Authors:  Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

2.  Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.

Authors:  D Y C Heng; T K Choueiri; B I Rini; J Lee; T Yuasa; S K Pal; S Srinivas; G A Bjarnason; J J Knox; M Mackenzie; U N Vaishampayan; M H Tan; S Y Rha; F Donskov; N Agarwal; C Kollmannsberger; S North; L A Wood
Journal:  Ann Oncol       Date:  2014-01       Impact factor: 32.976

3.  Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy.

Authors:  Alexander C Small; Che-Kai Tsao; Erin L Moshier; Benjamin A Gartrell; Juan P Wisnivesky; James H Godbold; Cardinale B Smith; Guru Sonpavde; William K Oh; Matthew D Galsky
Journal:  Cancer       Date:  2012-06-15       Impact factor: 6.860

4.  Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database.

Authors:  Marc C Smaldone; Elizabeth Handorf; Simon P Kim; R Houston Thompson; Brian A Costello; Anthony T Corcoran; Yu-Ning Wong; Robert G Uzzo; Bradley C Leibovich; Alexander Kutikov; Stephen A Boorjian
Journal:  J Urol       Date:  2014-10-23       Impact factor: 7.450

5.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Trends in the use of cytoreductive nephrectomy in the United States.

Authors:  Che-Kai Tsao; Alexander C Small; Erin L Moshier; Benjamin A Gartrell; Juan P Wisnivesky; Guru Sonpavde; James H Godbold; Michael A Palese; Simon J Hall; William K Oh; Matthew D Galsky
Journal:  Clin Genitourin Cancer       Date:  2012-05-30       Impact factor: 2.872

7.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245
  7 in total
  1 in total

1.  The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma.

Authors:  Reza Mehrazin; Essel Dulaimi; Robert G Uzzo; Karthik Devarjan; Jianming Pei; Marc C Smaldone; Alexander Kutikov; Joseph R Testa; Tahseen Al-Saleem
Journal:  Ther Adv Urol       Date:  2017-10-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.